Dr. Mehta will study the use of Quercetin, a naturally occurring flavonoid (antioxidant) in patients with Fanconi anemia, one of the most common congenital bone marrow failure syndromes. She anticipates that the results of this pilot study will show that long term oral Quercetin therapy is feasible and well tolerated in patients with Fanconi anemia. These results will form the basis of the continuation phase of the study, which will demonstrate that Quercetin therapy in fact delays or prevents progressive marrow failure in children with Fanconi anemia.
Dr. Mehta is studying the use of Quercetin, a naturally occurring flavonoid (antioxidant) in patients with Fanconi anemia, one of the most common congenital bone marrow failure syndromes. She anticipates that the results of this pilot study will show that long term oral Quercetin therapy is feasible and well tolerated in patients with Fanconi anemia. These results will form the basis of the continuation phase of the study, which will demonstrate that Quercetin therapy in fact delays or prevents progressive marrow failure in children with Fanconi anemia.
Progress in Dr. Mehta’s study was slower than expected due to some regulatory delays and the limited availability of Quercetin, but all approvals and quality assurance testing have been completed and she and her colleagues are in the process of contacting eligible study participants.